Unformatted text preview: SEASE-MODIFYING STRATEGIES
STUDY Parallel groups with survival to a clinically meaningful endpoint (ex. conversion from MCI to AD).
Addition of novel treatment or placebo to ‘standard care’. © TND 2005 Percent without AD diagnosis Hypothetical MCI Trial with Delay to AD
as Primary Endpoint
50 Placebo 0 Time in Months 36
© TND 2005 Add-On Design Performance Cholinesterase Inhibitor &
Disease Modifying Agent
Stable Dose of
Cholinesterase Inhibitor &
Placebo -3 0 12
© TND 2005 DISEASE MODIFYING STRATEGIES
FOR AD: TREATMENT OPTIONS
FOR Control of vascular risk factors Antiinflammatory drugs Postmenopausal hormonal therapy Inhibition of beta secretase Immunotherapy (“vaccine”) Inhibition of fibrillogenesis Antioxidants Statins
© TND 2005 CONCLUSIONS CI offer useful benefit in AD and mixed AD/VaD. Treatment expectations should be a stabilization of decline of cognition, functional autonomy and behavior over time.
Switching between CI is possible.
Future improvements will be in modifying disease progression. © TND 2005...
View Full Document
- Fall '13
- Physiology, placebo, donepezil, TND